Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
bluebird bio, Inc. - Common Stock
(NQ:
BLUE
)
4.970
UNCHANGED
Last Price
Updated: 4:00 PM EDT, May 30, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about bluebird bio, Inc. - Common Stock
< Previous
1
2
...
11
12
13
14
15
16
17
18
19
...
22
23
Next >
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
January 18, 2023
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
↗
January 18, 2023
We're starting the day with a breakdown of the biggest pre-market stock movers traders will want to watch on Wednesday morning!
Via
InvestorPlace
bluebird bio, Inc. Announces Proposed Public Offering of Common Stock
January 18, 2023
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Provides Update on Commercial Launch Progress, Program Milestones and 2023 Financial Outlook Ahead of Company Presentation at 41st Annual J.P. Morgan Healthcare Conference
January 09, 2023
From
bluebird bio, Inc.
Via
Business Wire
2 Risky Stocks That Could Soar in 2023
↗
December 06, 2022
These "exciting" companies aren't for everyone.
Via
The Motley Fool
Looking Into bluebird bio's Return On Capital Employed
↗
November 30, 2022
Via
Benzinga
2 Stocks That Could Double Your Money in 2023
↗
January 07, 2023
These biotechs could crush the market, but there is more to the story.
Via
The Motley Fool
bluebird bio Sells Second Priority Review Voucher for $95 Million
January 06, 2023
From
bluebird bio, Inc.
Via
Business Wire
Newly Approved Drugs In US Command Over $200,000 On An Average
↗
January 05, 2023
The median annual price of 17 new drugs approved by the FDA since July 2022 reached $193,900, down from $257,000 in 1H of 2022. For the full year 2022, the median price was $222,003.
Via
Benzinga
bluebird bio to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 05, 2023
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Appoints Joseph Vittiglio, JD, as Chief Business and Legal Officer
January 03, 2023
From
bluebird bio, Inc.
Via
Business Wire
Analyst Ratings for bluebird bio
↗
November 08, 2022
Within the last quarter, bluebird bio (NASDAQ:BLUE) has observed the following analyst ratings:
Via
Benzinga
1 Cathie Wood Stock to Buy While It's Affordable, and 1 to Avoid (for Now)
↗
December 30, 2022
Both stocks have fallen brutally this year, but only one has a chance to recover soon.
Via
The Motley Fool
After Doubling in the Past 6 Months, Is This Stock a Buy?
↗
December 24, 2022
This company has had a solid year, but there is still plenty of work ahead.
Via
The Motley Fool
FDA Allows Bluebird Bio To Resume Sickle Cell Disease Studies In Patients Below 18, With Changed Protocol
↗
December 19, 2022
Via
Benzinga
BLUE Stock Alert: What to Know as the FDA Lifts Hold on Bluebird Bio Treatment
↗
December 19, 2022
In a counterintuitive move, traders are selling BLUE stock even as Bluebird Bio claims to be on track with its sickle cell disease treatment.
Via
InvestorPlace
FDA Lifts Partial Clinical Hold for bluebird bio’s Sickle Cell Disease (SCD) Studies for Patients Under the Age of 18
December 19, 2022
From
bluebird bio, Inc.
Via
Business Wire
Magenta Therapeutics Shares Surge After Encouraging Data From Blood Cancer Candidate At ASH Meeting
↗
December 13, 2022
Via
Benzinga
Why Bluebird Bio Stock Crushed the Market Today
↗
December 12, 2022
The company looks set to continue its good momentum in the early part of next year.
Via
The Motley Fool
New Data from bluebird bio’s Gene Therapies for Transfusion-Dependent Beta-Thalassemia and Sickle Cell Disease Presented at 64th ASH Annual Meeting
December 10, 2022
From
bluebird bio inc.
Via
Business Wire
What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers
December 06, 2022
Since Robert Hooke discovered cells in 1665 and Theodor Schwann proposed the classical cell theory in 1839, the cell therapy industry has grown by leaps and bounds.
Via
TheNewswire.com
What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers
December 06, 2022
By Ernest Dela Aglanu, Benzinga
Via
News Direct
Why CSL Ltd Stock Could Be Worth a Look
December 03, 2022
FDA approval of costly--but worthwhile--drug leads the momentum that could make CSL Ltd an equally worthwhile investment.
Via
MarketBeat
Bluebird Bio Sells Priority Review Voucher For $102M, Strengthening Its Financial Position
↗
November 30, 2022
Via
Benzinga
bluebird bio Sells Priority Review Voucher for $102 Million
November 30, 2022
From
bluebird bio, Inc.
Via
Business Wire
FDA Approves UniQure's Hemgenix, First Hemophilia B Gene Therapy For Adults
↗
November 23, 2022
Via
Benzinga
Where Will Editas Medicine Be in 1 Year?
↗
November 20, 2022
The company could continue lagging the market for a while.
Via
The Motley Fool
2 Growth Stocks That Could Double in 2023
↗
November 17, 2022
Both are lagging the market this year.
Via
The Motley Fool
Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday
↗
November 08, 2022
Gainers
Via
Benzinga
Spirit AeroSystems, Oyster Point Pharma, Snap And Other Big Gainers From Monday
↗
November 08, 2022
U.S. stocks closed higher on Monday, with the Dow Jones surging more than 400 points. Here is the list of some big stocks recording gains in the previous session.
Via
Benzinga
< Previous
1
2
...
11
12
13
14
15
16
17
18
19
...
22
23
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
